# CORE-HH (Harbinger Health test development and validation)

Source: https://onco.cc/trials/core-hh/  
OnCo record `core-hh` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The study of about 8,000 people that Harbinger Health used to build and validate its blood test for many cancers.

## Summary

CORE-HH (NCT05435066) is an observational study sponsored by Harbinger Health. It collected blood, tissue and clinical data from people with a variety of cancers and from people without cancer to develop a screening test for early cancer detection.

The registry record, read on 29 October 2026, gives its status as completed, with 8,038 participants enrolled, a start on 21 June 2022 and primary completion on 11 June 2025.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-10-29
- Also known as: CORE-HH; Cancer ORigin Epigenetics-Harbinger Health
- Registry id: NCT05435066
- Phase: observational
- Setting: People with solid and blood cancers and people without cancer at more than 100 US sites, giving blood and tissue to develop a blood-based multi-cancer screening test
- Sponsor: Harbinger Health
- Enrolled: 8038

## Sources

- ClinicalTrials.gov NCT05435066: https://clinicaltrials.gov/study/NCT05435066

## Connected records

- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- drugs: [RESOLVE (Harbinger Health)](https://onco.cc/drugs/harbinger-resolve/)
- companies: [Harbinger Health](https://onco.cc/companies/harbinger-health/)
- trials: [PROCARES (Harbinger Health diagnostic aid in people with suspected cancer)](https://onco.cc/trials/procares/)

---
JSON: https://onco.cc/api/v1/entities/core-hh.json